Adjuvant intravesical chemotherapy of superficial @entity150 with monthly @entity632 or intensive XXXX . A comparison of two consecutive series.

@entity1 @entity632 @entity137 @entity1138 @entity2802 @entity150
120 @entity1 with the first occurrence of @entity2802 stage Ta or T1 @entity150 were given adjuvant intravesical treatment in 2 consecutive series. The first 60 received @entity632 monthly for 6 months, then on the 9th and 12th month following surgery. The second series was given @entity1138 weekly for 2 months, then monthly to the end of the first year. Median follow-up is 48 months in the first series and 15 in the second. In the @entity632 group, 28 @entity1 had recurrences. The recurrence rate is 1.86/100 @entity1 -months. Seventeen of these first relapses occurred within the first year. In the 'intensive' @entity1138 series, where 36 @entity1 were observed for 12 months or more, 3 relapsed. The recurrence rate to date is 0.35. The relapse-free survival probability at 12 months is 75% in the first series and 93% in the second. Treatment was stopped due to @entity137 in 4 @entity1 in the @entity632 group and in 10 of the @entity1138 group.
